Member Info for smeeagainbruce

Muck165, suggest you listen to the excellent video Almostrich posted on Project Optimus / FDA strategies for dose finding and dose optimisation will dictate how future trials are carried out. It is obvious imo Avct is being led down this path. MTD is no longer the prime objective anymore, the video describes the drug Idelalisib trial where they missed the chance finding the most advantageous dosing regime. Dosing the MTD with this drug made Gilead withdraw the drug for its toxicity, research found a lower dose worked better. Great video, needs many viewings to appreciate its content imo.

A Radioconjugate has four parts, a radioactive isotope, a chelating agent ( can have serious even life threatening side effects ), a linker and a targeting molecule. Tech bought by AstraZeneca for $2.4 billion.

Eli Lilly bought Point bio for $1.4 billion, question is who got the best deal.

EL have CanSEEK / pre|CISION which can be used in the linker, a clinically validated targeting technology allowing the warhead to be released on target.

AZ have a targeting molecule to release the warhead.

I am no scientist, however the validated targeting system at the sale price of $1.4 billion has the edge imo.

Got really worried for AZ when one of the targeting vehicles to be used was a mAb. To be fair they also listed small molecules or peptides.

Since pre|CISION is a simple di-peptide maybe AZ will follow a tried and tested targeting vehicle and go for the simple peptide route targeting PSMA. Whatever it still has to pass muster,

Touk, did they find the MTD in the pre-clinical trials with the mouse models, answer is yes. FMcL stated it was 2mg/kg, have they found MTD for humans, answer is no. On this evidence why would it not be a surprise results were better than expected.

you state; " The Rat ?? trials certainly predicted those results". No they did not, flogging a dead horse comes to mind. I give up bye.

Touk ; your latest opinion is shot down by fact. " I think there is a possibility that excretion exceeds cleaving rate for some patients characteristics hence 2 week dosing trial". your opinion.

https://www.youtube.com/watch?v=eqj0hhgmX6U

Watch the video 16 min in and CC tells you why the 2 week dosing trial is being adopted.

Fact, it is because of the excellent safety profile, your opinion is therefore unfounded.

SARC is a non profit making cancer research organisation and is the leader in clinical trials for Sarcoma patients.

Episode 14; several of the topics covered include problems with funding / patient enrolment and clinical trials.

A very interesting comment was made in the video presentation starting ( 19min 57 sec in )

https://www.youtube.com/watch?v=9weuscZgwKM

Steven Young the CEO of SARC talks about encouraging positive projects to bear fruit and having positive readouts. He then goes on to say, can't say more than that, none of us can talk about this yet. He goes on to say, this ASCO should be very interesting for the Sarcoma world ?

Notrex, your maths is flawed ABDX 8p / Avcta 52p, this is not a 1/16th of the difference, could be around a 1/6th using my old slide rule. Your 3 - 4 pence valuation of Avct is therefore also flawed.

In your own words , "Lets get real".

Please facts only, opinions based on flawed maths is not good. Would you care to try again !!!

Astrea Bioseparations were taken over by Biotage, it is unlikely Biotage will get a mention. More important info to be discussed.

"buy"

About AVA6000

AVA6000, Avacta Therapeutics' lead oncology program, is a peptide drug conjugate consisting of doxorubicin conjugated with a peptide moiety that is specifically cleaved by fibroblast activation protein (FAP) in the tumor microenvironment (TME). FAP is selectively overexpressed in many solid tumors. The peptide moiety (pre|CISIONTM) prevents cellular entry of doxorubicin unless cleaved by FAP, thus enabling targeted delivery of doxorubicin directly to the TME.

We have been informed by AS pre|CISION works, it is a simple Di-Peptide chemistry. We can use pre|CISION in the linker in drug Conjugates to allow the warhead to be released. The platform does exactly what it is designed to do.

Unless I am mistaken this blows wide open the doors of the ADC technology, really worrying if you are Pfizer and splashed out $43 billion to by Seagens ADC's and their expertise in the market.

In short a simple piece of chemistry can be used in the linker in a drug conjugate. ADC's have 3 components , Antibody, a linker and a cytotoxic moiety. Is it my lack of understanding the technology makes me believe Avct are on to something big here. Maybe the chemists among you can burst my bubble.

The General returns to the front line spouting out his opinions ;

"The big error was not progressing the diagnostics pipeline since the LFT. Do Affimers not work as well as claimed? Are they not a viable alternative to antibodies? Have they not got enough capital to invest in the diagnostics? Progress here would’ve derisked the therapeutics risk for investors."

His recent battle plans have failed miserably, the need for a phase 3, Affimer v Antibody in the LFD and his embarrassing lack of knowledge sums up the quality of his posts. Try producing a fact, chew on this one, Affimers were produced which inhibited the covid virus entering human cells, in other words a potential treatment. Google Prof Dr David Bhella ( Centre for Virus Research, Glasgow University ) and educate yourself.

GeneralOz attempted to educate you on the LFT facts and obviously failed, now you come up with another quote which frankly places you in the HAVE NOT A CLUE brigade. I will attempt to educate you the phase 3 post and frankly I have a feeling this will also fall on fallow ground.

"So if it works 'unequivocally' why did say they now need to do a phase 3 trial in the latest RNS?"

Firstly had to read it a few times " why did say they now", luckily I retained my old Enigma machine and you want to know why the trial is now going through a phase 3 trial. Now listen very carefully, I shall say this one more time just for you.

THE AVA 6000 ONGOING PHASE 1 & 2 TRIAL TARGETING STS WILL NOT (GET THIS ) WILL NOT REQUIRE A PHASE 3. The reason for this has been posted on numerous occasions and frankly spending the time to put you right is pointless. You are not interested in fact only posting opinions which imo demonstrates your lack of knowledge. In short go away and do some due diligence, you are embarrassing yourself. Question, are you and Charles Archer related !!!!

Piper, this was discussed a few days ago, the CA article is flawed and it is clear his knowledge of the technology is limited. Opinions / interpretations not based on fact, his interpretation of the phase 2 / 3 requirements is embarrassing. Maybe you can answer the question he asks in regard to the LFT " Cytiva anyone". !!

Lessons Learned article he claims, certainly was for me, Mr Charles Archer speaks with forked tongue.

Have just read his article, the mans a joke, his understanding of the technology is embarrassing, not once has the man mentioned pre|CISION works. He rattles on about a follow on Phase 3 study stating the previous argument was that Phase 3 would be unnecessary. Maybe with all the bullsh.t being thrown around I have completely mis-understood Avct's plan, get ODD approval for AVA6000 in rare STS patients and go on from there with say breast cancer which will require a full clinical trial.

He claims to have tried to warn investors a placing was imminent, only an opinion of course. Reality is the market knew well in advance this was the case and not to raise suspicion slowly carved away at the SP.

The statement which really p.ssed me off " the placing could have been much higher if it had been managed properly "

Say Avct applied for a placing at 90p, this is deemed to high a price, word gets around and the big sell off begins leaving the small fry to figure out what is taking place. It should not happen but it does, criminal.

As for his attempt at that old chestnut the LFT, we get this " CYTIVA anyone". Anybody got a clue what he is on about, the fact is Cytiva could not deliver the goods. Maybe he was confused and meant Mologic who went on to design the LFD and added the duff mAb. What he omitted to say was Avct's sole input into the farce was the Affimer they produced and low and behold it was not affected in performance by any of the virus variants, it worked. Not like the other participants who got involved in the process, they delivered delays / inferior products to the process.

KOKO has asked for comments on his article, the little box he provided is totally inadequate, so many flawed views. Crammed a few comments in the Archer of all trades Master of none box.

Check out Moses posts, member since 16th Feb 2024, on the 21st Feb (FUNDING ) he said right now the rumour is Avct is working on a funding, its going to effect the price ,watch this space.

In his latest post he reveals working in the city & can't reveal who he is.

Hope the good samaritan didn't profit from his insider information. The 10th commandment forbids greed, he knows that I'm sure !!

He never once mentioned pre|CISION worked which in my mind explains his short sighted opinions. Doxorubicin is one drug is a vast array of drugs in the market. AS said cytotoxic drugs have come a long way in the last few years and there are far more toxic drugs out there which could not be used because of their toxicity. He also said we can use pre|CISION in the linker in drug conjugates to allow the warhead to be released, the platform is is doing exactly what it is designed to do.

The platform lends itself not only treating cancer, it can be used in viral / Inflammatory diseases. Mr C A imo doesn't see the big picture. There are around 14 approved ADC's using far more potent cytotoxins compared to Dox, the market is massive and the side effects remain an issue. In the brackets provided please state your reasons why the pre|CISION platform would not be sought after by BP. ( ).

JWB, if you call avct you will be put on hold and this song is blasting away.

https://www.youtube.com/watch?v=FEFPLQ_Cofc

Don't worry if you can't understand the connection, with 516 posts in the last 30 days your overall understanding of the companies technology is no doubt limited. Happy trading.

Is, a "pratfall" meaning when a prat falls on his ar.e. Hilarious, works every time can't stop laughing. Regular visits to the circus would be appreciated, can't beat a good laugh.

CTSFO, watch the video and see why they didn't decide on a fortnightly trial without very good reason. Simple explanation delivered by CC, enjoy.

https://www.youtube.com/watch?v=eqj0hhgmX6U

Good spot by LLP on 8th Feb, unfortunately much of the informative posts on here are lost. Wonder why !!

Https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7684756/

As stated in the link; the required cumulative Dox dose in STS treatment was based on cardiotoxicity data from studies of Breast Cancer patients. The treatment and prognosis of BC & STS are quite different & reference to to BC data alone may not reflect the efficacy of Dox in STS treatment.

This comprehensive study concludes a high cumulative dose of Dox for advanced STS was associated with better efficacy.

Phase 1 ARM 2 delivers the recommendations made in this study. Happy Days.